2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD38
  5. CD38 Inhibitor

CD38 Inhibitor

CD38 Inhibitors (6):

Cat. No. Product Name Effect Purity
  • HY-134358A
    Ara-F-NAD+ sodium
    		Inhibitor
    Ara-F-NAD+ sodium is an arabino analogue of NAD+. Ara-F-NAD+ sodium is a potent, reversible and slow-binding CD38 NADase inhibitor.
  • HY-P99730
    Mezagitamab
    		Inhibitor
    Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
  • HY-P99616
    Felzartamab
    		Inhibitor
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research.
  • HY-150508
    MK-0159
    		Inhibitor 99.72%
    MK-0159 (compound 37) is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
  • HY-134358
    Ara-F-NAD+
    		Inhibitor
    Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor.
  • HY-P99744
    Modakafusp alfa
    		Inhibitor
    Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules. Modakafusp alfa can be used in the research of multiple myeloma.